drugset / Trial / NCT04746963
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
Non-randomizedSequentialOpen-labelTreatment
Summary
This is an open-label, dose-escalating, 48-week study assessing the safety, tolerability, bioactivity and duration of action of a single intravitreal injection of 0.1 mg, 0.25 mg, or 0.5 mg AXT107 in approximately 18 subjects (up to 6 subjects per dose) with nAMD.
Timeline
- Start
- 2021-02-01
- Primary completion
- 2022-10-01
- Completion
- 2022-10-01
Outcome
Outcome not reported
Stopped: “Adverse Events”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GERSIZANGITIDE | Protein / enzyme biologic | 0.1 mg | Intravitreal |
| Subject | GERSIZANGITIDE | Protein / enzyme biologic | 0.25 mg | Intravitreal |
| Subject | GERSIZANGITIDE | Protein / enzyme biologic | 0.5 mg | Intravitreal |